Profund Advisors’s Janux Therapeutics JANX Stock Holding History

Profund Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$414K	Sell	26,973 -6,803	-20%	-$98.5K	0.01%	632
2026 Q1	$469K	Sell	33,776 -30,246	-47%	-$415K	0.02%	569
2025 Q4	$884K	Buy	64,022 +47,584	+289%	+$1.12M	0.03%	379
2025 Q3	$402K	Buy	16,438 +6,386	+64%	+$156K	0.01%	608
2025 Q2	$232K	Sell	10,052 -1,674	-14%	-$44.1K	0.01%	818
2025 Q1	$317K	Buy	11,726 +1,520	+15%	+$57.3K	0.01%	646
2024 Q4	$546K	Sell	10,206 -2,806	-22%	-$148K	0.02%	476
2024 Q3	$591K	Sell	13,012 -1,262	-9%	-$54.9K	0.02%	466
2024 Q2	$598K	Buy	+14,274	New	+$670K	0.02%	448

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Profund Advisors's JANX Position: Q2 2026 in Review

Profund Advisors reduced its Janux Therapeutics (JANX) stake by 20% in Q2 2026, selling an estimated $98.5K and leaving 26,973 shares worth $414K. The position accounts for 0.01% of the portfolio, ranked #632.

Profund Advisors first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $884K in Q4 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Profund Advisors held 26,973 shares of Janux Therapeutics worth $414K as of Q2 2026.
Profund Advisors sold 6,803 Janux Therapeutics shares in Q2 2026, an estimated $98.5K.
Janux Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #632 holding.
Profund Advisors first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
Profund Advisors's Janux Therapeutics position peaked at $884K in Q4 2025.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.